Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Autoimmune diseases induced by biological agents: a double-edged sword?
Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA; BIOGEAS Study Group. Ramos-Casals M, et al. Autoimmun Rev. 2010 Jan;9(3):188-93. doi: 10.1016/j.autrev.2009.10.003. Epub 2009 Oct 23. Autoimmun Rev. 2010. PMID: 19854301 Review.
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts.
Díaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martínez-Berriotxoa A, García-Hernández F, Callejas-Rubio JL, Rascón J, D'Cruz D, Jayne D, Ruiz-Irastorza G, Emery P, Isenberg D, Ramos-Casals M, Khamashta MA; UK-BIOGEAS Registry. Díaz-Lagares C, et al. Autoimmun Rev. 2012 Mar;11(5):357-64. doi: 10.1016/j.autrev.2011.10.009. Epub 2011 Oct 18. Autoimmun Rev. 2012. PMID: 22032879
Rituximab therapy in lupus nephritis: current clinical evidence.
Ramos-Casals M, Diaz-Lagares C, Soto-Cardenas MJ, Brito-Zeron P, Cuadrado MJ, Sanna G, Bertolaccini L, Khamashta MA. Ramos-Casals M, et al. Clin Rev Allergy Immunol. 2011 Jun;40(3):159-69. doi: 10.1007/s12016-010-8205-3. Clin Rev Allergy Immunol. 2011. PMID: 20419398 Review.
Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.
Díaz-Lagares C, Pérez-Alvarez R, García-Hernández FJ, Ayala-Gutiérrez MM, Callejas JL, Martínez-Berriotxoa A, Rascón J, Caminal-Montero L, Selva-O'Callaghan A, Oristrell J, Hidalgo C, Gómez-de-la-Torre R, Sáez L, Canora-Lebrato J, Camps MT, Ortego-Centeno N, Castillo-Palma MJ, Ramos-Casals M; BIOGEAS Study Group. Díaz-Lagares C, et al. Arthritis Res Ther. 2011 Jul 11;13(4):R112. doi: 10.1186/ar3397. Arthritis Res Ther. 2011. PMID: 21745378 Free PMC article.
Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases.
Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M, Retamozo S, Bové A, Bosch X, Sanchez-Tapias JM, Forns X, Ramos-Casals M; BIOGEAS Study Group. Pérez-Alvarez R, et al. Medicine (Baltimore). 2011 Nov;90(6):359-371. doi: 10.1097/MD.0b013e3182380a76. Medicine (Baltimore). 2011. PMID: 22033451 Free article.
32 results